×
For best experience we recommend to activate Javascript in your browser.
MARK1 antibody (N-Term)
This Rabbit Polyclonal antibody specifically detects MARK1 in WB, ELISA and IHC. It exhibits reactivity toward Human.
Quick Overview for MARK1 antibody (N-Term) (ABIN2307865)
Target
See all MARK1 Antibodies
MARK1
(MAP/microtubule Affinity-Regulating Kinase 1 (MARK1))
Reactivity
All reactivities for MARK1 antibodies
Human
Host
All hosts for MARK1 antibodies
Rabbit
Clonality
All clonalities for MARK1 antibodies
Polyclonal
Conjugate
All conjugates for MARK1 antibodies
This MARK1 antibody is un-conjugated
Application
All applications for MARK1 antibodies
Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
Product Details anti-MARK1 Antibody
(hide)
Binding Specificity
All epitopes for MARK1 antibodies
AA 16-45, N-Term
Cross-Reactivity
Human, Mouse (Murine)
Cross-Reactivity (Details)
Calculated cross reactivity: Hu Mo
Characteristics
MARK1, NT (MARK1, KIAA1477, MARK, Serine/threonine-protein kinase MARK1, MAP/microtubule affinity-regulating kinase 1, PAR1 homolog c)
Purification
Purified by Protein G affinity chromatography.
Immunogen
MARK1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 16~45 amino acids from the N-terminal region of human MARK1.
Isotype
IgG
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working conditions should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Buffer
Supplied as a liquid in PBS, pH 7.2, 0.09 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Storage Comment
-20°C
Target Details for MARK1
(hide)
Target
MARK1
(MAP/microtubule Affinity-Regulating Kinase 1 (MARK1))
Alternative Name
MARK1
UniProt
Q2HIY1
Pathways
SARS-CoV-2 Protein Interactome , The Global Phosphorylation Landscape of SARS-CoV-2 Infection
Recently viewed
(hide)
Chat with us , powered by LiveChat